EP1453955A2 - Construits cellulaires cultives in vitro, preparation et utilisations - Google Patents
Construits cellulaires cultives in vitro, preparation et utilisationsInfo
- Publication number
- EP1453955A2 EP1453955A2 EP02804924A EP02804924A EP1453955A2 EP 1453955 A2 EP1453955 A2 EP 1453955A2 EP 02804924 A EP02804924 A EP 02804924A EP 02804924 A EP02804924 A EP 02804924A EP 1453955 A2 EP1453955 A2 EP 1453955A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- construct
- tissue
- cell
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000338 in vitro Methods 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 284
- 210000001519 tissue Anatomy 0.000 claims abstract description 145
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 52
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 52
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 52
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 35
- 210000004102 animal cell Anatomy 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 230000033558 biomineral tissue development Effects 0.000 claims description 65
- 239000007943 implant Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 230000001413 cellular effect Effects 0.000 claims description 30
- 239000011159 matrix material Substances 0.000 claims description 24
- 210000003041 ligament Anatomy 0.000 claims description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 22
- 108010035532 Collagen Proteins 0.000 claims description 22
- 229920001436 collagen Polymers 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 20
- 230000011164 ossification Effects 0.000 claims description 20
- 210000000515 tooth Anatomy 0.000 claims description 20
- 239000002609 medium Substances 0.000 claims description 19
- 210000002379 periodontal ligament Anatomy 0.000 claims description 19
- 210000002950 fibroblast Anatomy 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 230000001089 mineralizing effect Effects 0.000 claims description 14
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 13
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 13
- 210000000988 bone and bone Anatomy 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 210000002435 tendon Anatomy 0.000 claims description 11
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 210000000250 cementoblast Anatomy 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 8
- 210000000963 osteoblast Anatomy 0.000 claims description 8
- 230000003239 periodontal effect Effects 0.000 claims description 8
- 238000005096 rolling process Methods 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000005312 bioglass Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 238000007634 remodeling Methods 0.000 claims description 5
- 235000014653 Carica parviflora Nutrition 0.000 claims description 4
- 241000243321 Cnidaria Species 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 239000003636 conditioned culture medium Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 210000004523 ligament cell Anatomy 0.000 claims description 4
- 239000005445 natural material Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 238000004804 winding Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 239000000316 bone substitute Substances 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000008439 repair process Effects 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000004744 fabric Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 239000000835 fiber Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108060005980 Collagenase Proteins 0.000 description 8
- 102000029816 Collagenase Human genes 0.000 description 8
- 210000001612 chondrocyte Anatomy 0.000 description 8
- 229960002424 collagenase Drugs 0.000 description 8
- 238000002513 implantation Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 238000004873 anchoring Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 4
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 4
- 102000004067 Osteocalcin Human genes 0.000 description 4
- 108090000573 Osteocalcin Proteins 0.000 description 4
- 102000004264 Osteopontin Human genes 0.000 description 4
- 108010081689 Osteopontin Proteins 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 239000004568 cement Substances 0.000 description 4
- 239000004053 dental implant Substances 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000012432 Collagen Type V Human genes 0.000 description 3
- 108010022514 Collagen Type V Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 3
- 239000005313 bioactive glass Substances 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004268 dentin Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000001053 ameloblast Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000004416 odontoblast Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 1
- 108010013295 Microbial collagenase Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000011412 natural cement Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/386—Ligaments, tendons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3865—Dental/periodontal tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/066—Tenocytes; Tendons, Ligaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
- C12N2533/18—Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
Definitions
- the present invention relates to the technical fields of biology, biotechnology, toxicology, pharmacology and medicine. Its applications relate in particular to the fields of human and animal health. More particularly, the invention describes new methods of culturing and reconstituting human or animal tissues in vitro or ex vivo, typically from the cells which compose them. These methods make it possible to preserve the differentiation capacities of the cells used while orienting this differentiation in the desired direction.
- the invention also relates to the cell constructs and the tissues thus reconstituted, as well as the numerous uses that can be made of them. It also relates to tools and kits for the implementation of these methods.
- the invention is particularly useful in the field of grafts or implantology (tissue reconstruction or repair), as well as in the pharmaceutical industry, for the study of tissues and the analysis of the toxic or beneficial profile of molecules capable of '' enter pharmaceutical development and / or pharmaceutical compositions.
- Tissue reconstruction combines methods of bioengineering with the principles that govern the life sciences so as to understand the structural and functional interconnections of normal and pathological tissues in mammals.
- One of the objectives is to produce biological substitutes to test, restore, maintain or improve biological functions in vitro or in vivo, and to produce in vitro tissues or cellular constructs as similar as possible to the native tissues that one seeks to rebuild.
- the use of cells from higher eukaryotic organisms, for experimental (genetic studies, toxicity studies, etc.), pharmacological or therapeutic (cell therapy, tissue repair, etc.) needs has undergone very significant development. To do this, different methods of obtaining cells or tissues have been developed, in particular for the preparation of primary cell cultures, based essentially on the taking and ex vivo treatment of a biopsy.
- tissue cultures for example vessels
- tissue cultures have been able to be produced in the absence of synthetic matrix or porous membrane, they are essentially limited to particular tissues and do not have characteristics suitable for direct therapeutic use.
- the problem which the present invention proposes to solve consists in obtaining a functional cell construct capable of integrating biologically into the tissues of a recipient host subject, thanks to the resources of the cells of said construct and to the properties of said construct.
- Particularly advantageous tissues within the meaning of the invention are tissues capable of behaving functionally when grafted to a recipient host, that is to say of incorporating or integrating in a durable manner with the inside this host and / or to be gradually reshaped by the cells of the host, with the aim of filling, repairing or restoring defective properties.
- a first particular aspect of the invention relates to reconstituted or cellular constructed tissues comprising cells having a capacity for mineralization and / or ossification.
- Another aspect of the invention relates to reconstructed cellular constructs or tissues capable of incorporating or integrating in a sustainable manner inside a host and comprising zones of mineralization and / or ossification.
- tissues or cellular constructs of the invention can be produced from different cell types, alone or in combinations, in particular of ligament, tooth, bone, tendon cells, and comprise an extracellular matrix in which said cells are coated.
- a specific aspect of the invention resides in tissue reconstituted from ligament cells, in particular from the periodontal ligament.
- Another particular aspect of the invention is to provide reconstituted tissues having a significant thickness, typically greater than or equal to approximately 100 ⁇ m, in particular in which the cells and the matrix are functionally organized.
- the present invention relates to cellular (or constructed) tissues reconstituted from animal cells, preferably from mammals, for example human cells, cultured in vitro without the intervention of a framework or synthetic matrix intended to give its hold to the fabric.
- the cell constructs can thus advantageously be produced only using animal cells, preferably mammals, for example human cells, and components of endogenous extracellular matrix (Le., Produced by these cells).
- a therapeutic composition comprising a reconstituted cellular tissue as defined above.
- the invention provides in particular cellular dressings (or bioactive dressings) comprising a reconstituted tissue or cell mass as defined above, and intended for implantation in a subject.
- the invention also relates to methods of tissue treatment or repair, comprising the preparation of a reconstituted tissue and its implantation in a subject, in an autologous, allogenic or xenogenic context, preferably in an autologous context.
- the invention can be used for the treatment or repair of tissue defects in subjects, for the preparation of implants, for carrying out tests in vitro or ex vivo, etc.
- the present invention relates to cell constructs prepared in vitro, their production and their uses.
- animal cells cultivated in vitro under conditions ensuring the formation of a three-dimensional tissue structure, and (ii) an endogenous extracellular matrix in which said cells are trapped, and in that it comprises, among said cells , cells with a mineralization and / or ossification capacity.
- the term “construct” or “cellular construct” designates a cluster or cellular tissue in the form of a spread construct. It can be a cluster or tissue comprising one or more layers of cells superimposed on each other, typically from 1 to 20 layers of cells, preferably from 2 to 15 layers approximately. Construct cells are embedded in a dense three-dimensional network of extracellular matrix synthesized by the construct's own cells, and which gives its structure and resistance to the construct of the invention.
- construct designates, in general, an artificial tissue construct (that is to say in particular manufactured, cultivated or maintained in vitro) comprising one or more layers of cells cultured in vitro, coated in an extracellular matrix produced by said cells , construct cells being biologically active, Le., susceptible to division, proliferation, remodeling, release of biological factors, etc.
- construct cells being biologically active, Le., susceptible to division, proliferation, remodeling, release of biological factors, etc.
- the construct generally has a polarity, with a basal side and an apical side having different properties.
- tissue or cellular constructs reconstituted according to the invention lies in the fact that they can comprise cells which have retained a capacity for mineralization and / or ossification.
- the present application indeed shows that it is possible to artificially reconstitute tissues or constructed having the capacity of mineralization, thus creating mineralized zones.
- This aspect of the invention is particularly unexpected and important, since it allows the construction of tissues having biological properties adapted to the reconstruction of defects and / or having integration properties in a host greatly improved.
- the term cells having the capacity to produce mineralization / ossification cells producing, naturally or after particular stimulation, an enzymatic activity catalyzing the formation and / or the accumulation, in the extracellular matrix , calcium phosphate or calcium carbonate or a mixture of these different ions, typically in the form of particles, deposits, plates, etc.
- These are typically cells producing, under the culture conditions, alkaline phosphatase and / or complementary proteins (BMP, BSP, OPN, OCN, etc.), thus allowing the production of inorganic phosphate.
- BMP, BSP, OPN, OCN, etc. complementary proteins
- This mineralization generally leads to the creation of a mineralized and / or ossified face of the cell construct, which generally corresponds to that exposed to the culture support. As will be described in the following text, this face is also the richest in collagen. Indeed, the mineralization takes place in the middle of collagen fibers present in the construct, thus allowing a solid anchoring of the latter in the mineralization deposits. In addition, the progenitor cells increase in number near the culture support and facilitate the mineralization initiated by the matrix and the collagen network.
- This characteristic of the invention is particularly important and advantageous for the production of cellular constructs for repairing structures such as ligaments, tendons, teeth, bones, joints, etc., insofar as the production of mineralization promotes anchoring collagen fibers from the tissue in the mineralized layer and leads to a reconstituted tissue closer to the native tissue, in particular to a tissue including a cementum.
- the mineralizing cells of the constructs of the invention are typically cells of the mesenchyme or precursors of these cells. Their mineralization capacity is preserved by the culture and / or processing conditions of the cells in the construct, and / or due to the particular tissue origin of these cells.
- the reconstructed constructs or tissues according to the invention advantageously comprise animal cells, in particular mammalian cells, preferably human cells. They can be undifferentiated stem cells or cells derived from mature tissue, or a combination of such cells. If cells are taken from tissue mature, it can be any type of cell capable of producing the extracellular matrix and / or of conserving or acquiring a capacity for mineralization and / or ossification in particular under the influence of external factors. The cells involved in the reconstruction of the tissue can thus come from different cell populations, thus forming a heterogeneous population.
- cells derived from mature tissues such as muscle, bone, tooth, cartilage, tendon or ligament, in particular the tooth and the ligament, in particular the periodontal ligament or the anterior cruciate ligament.
- the cells when they come from the periodontium, they comprise, at least in the initial cultures, cells of the periodontal ligament, cells of the cementum and dentin, namely essentially fibroblasts (approximately 80%).
- the cells derived from the periodontal ligament typically include fibroblasts, epithelial cells, cementoblasts, osteoblasts and / or progenitors of these different cell types.
- odontoblasts When they come from the tooth, they include odontoblasts, ameloblasts, pulp cells, epithelial cells, cementoblasts and / or progenitors of these different cell types. It may also be a sample containing a majority of undifferentiated stem cells, the differentiation of which will be guided by appropriate culture means. It can also be chondrocytes or osteoblasts. These cells can originate from mesenchymal stem cells and / or cells isolated from an extract of bone marrow.
- the tissue according to the invention may be composed of a single cell population or of a combination or mixture of several cell types (or populations), distributed uniformly or not within the tissue so as to mimic the cell composition and structure of native tissue. If different cell types are present, it is preferable that at least one of said cell types is capable of mineralization and / or ossification.
- the cell type (s) having no mineralization capacity can (can) also be stimulated or transformed so as to induce mineralization and / or ossification.
- the cells of the construct for example fibroblasts
- the different cell populations can be associated at the start of the culture period, for example in a given ratio, or alternatively, for example by the association of several constructs.
- a particular object of the invention resides in a cell construct as defined above, produced from (or comprising) ligament cells cultured in vitro, in particular of periodontal or anterior cruciate ligament.
- the invention shows that artificial mineralized tissues can be made from this type of cells, which can be reshaped to produce thick constructs, and which have a functional biological organization.
- the tissues or constructs according to the invention comprise cells which are drowned or coated or trapped in an endogenous extracellular matrix, that is to say produced by the cells in culture.
- the extracellular matrix typically comprises (and essentially) a network of collagen fibers organized in particular into fibrils, sulfated proteoglycans, potentially involved in the regulation in vivo of the diameter of the fibrils, as well as simple or sulfated glycosaminoglycans (GAG).
- hyaluronic acid HA
- fibronectin a simple GAG
- di-hyaluronic acid di-chondroitin-O-sulfate
- di-chondroitin-4-sulfate di-chondroitin
- di-chondroitin can be found in particular -6-sulfate, di-chondroitin-4,6-sulfate, di-chondroitin-4-sulfate-UA-2S and / or di-chondroitin-6-sulfate-UA-2S.
- the extracellular matrix may further include decorin, such as biglycan or versicane, as well as tenascin, an extracellular matrix glycoprotein found particularly in mesenchyme or tissues under repair. It seems that the cells in culture gradually fill the space which separates them with a loose matrix rich in type III collagen and fibronectin and then reshape this matrix with type I collagen so as to make it denser.
- decorin such as biglycan or versicane
- tenascin an extracellular matrix glycoprotein found particularly in mesenchyme or tissues under repair.
- the construct comprises cells having the capacity to synthesize an endogenous extracellular matrix, the composition of which is similar to that found in the original tissue, except voluntary modifications (eg, incorporation of synthetic materials, modification cell genetics, etc.).
- the present invention relates to a construct as defined above comprising a basal layer and an apical layer relative to the culture support, said basal layer being rich in collagen and further comprising fibroblasts and cells progenitors responsible for mineralization and / or ossification and said apical layer being less rich in collagen than said basal layer, and typically comprising more proliferative cells.
- the constructions according to the invention can be of variable dimensions, both in surface area and in thickness. In addition, they can have or take forms varied. The dimensions and the shape can be adapted by a person skilled in the art or by the user, depending on the desired applications.
- a particular advantageous characteristic of the constructs or fabrics according to the invention lies in their substantial thickness, typically between 30 and 120 microns, preferably between 50 to 120 ⁇ m, even more preferably greater than or equal to approximately 100 ⁇ m.
- the present application indeed shows that it is possible to produce in vitro cell constructs having a high thickness, in which the cells are capable of organizing, differentiating and proliferating, to create a functional polarity in the construct without cause particular cell necrosis.
- This characteristic is advantageous because it provides a reconstituted tissue in which the cells organize and develop advantageous biological properties.
- the cells behave differently.
- the overall endogenous diffusion of substances within the tissue, and therefore in the environment of the cells is reduced, which increases the potential effect of the cells and leads to their reorganization and their remodeling.
- This organization also favors the appearance of mineralization, the polarization of the tissue, the expression of a proliferative layer on the apical surface, the holding of the construct and / or its integration in a subject.
- the thickness of the construct can be varied in different ways. Preferably, it is obtained artificially, for example by folding or rolling on itself a thinner construct, so as to increase its thickness by fusion and reshaping of the different cell layers.
- the invention indeed shows that it is possible to compact a first tissue construct comprising around 3 layers of cells obtained by culture, and that this compacting (eg, folding, winding, etc.) leads to a tissue in which the cells s '' organize, differentiate, and develop advantageous biological properties.
- the invention also shows that it is possible to cut a fabric or construct it in pieces which can then be folded or rolled up on themselves.
- the thickness can also be increased artificially by a separation of the edges of the construct which causes the retraction of the latter and the compacting of the cells.
- a particular object of the invention also resides in a cell construct, characterized in that it comprises (i) animal cells cultivated in vitro under conditions ensuring the formation of a three-dimensional tissue structure and (ii) an endogenous extracellular matrix in which said cells are coated (or imprisoned), and in that it has a thickness greater than or equal to approximately 100 ⁇ m.
- the construct comprises or is produced from cells having a mineralization capacity, and / or comprises or is produced from ligament, tendon, tooth or bone cells.
- a more particular object of the invention thus resides in a cell construct, characterized in that it comprises (i) cells taken from ligament, tendon, tooth and / or bone of mammal (s), cultivated in vitro in conditions ensuring the formation of a three-dimensional tissue structure, and (ii) an endogenous extracellular matrix in which said cells are coated (or imprisoned), and in that it has a thickness greater than or equal to approximately 100 ⁇ m.
- Another more preferred object of the invention thus resides in a cell construct, characterized in that it comprises (i) cells taken from ligament, tendon, tooth and / or bone of mammal (s), cultured in vitro under conditions ensuring the formation of a three-dimensional tissue structure, and (ii) an endogenous extracellular matrix in which said cells are coated (or imprisoned), in that it has a thickness greater than or equal to approximately 100 ⁇ m and in that it comprises cells having a mineralization capacity and / or mineralized zones.
- the construct has a basal layer (face) and an apical layer (face), the basal layer being rich in collagen and in mineralized zone.
- the surface of the construct or tissue can be adapted by a person skilled in the art by varying the quantity of cells seeded, the duration of the culture, the dimensions of the culture device, etc.
- building plots can be cut, having a shape suitable for the subsequent use of the construct, for example rectangular, square, circular, etc., and a surface also suitable for said use, for example between 1 and 20 cm 2 , preferably between 1 and 15 cm 2 , even more preferably between 2 and 10 cm 2 .
- the cell constructs are prepared by a method typically comprising: a) the culture of cells of interest under conditions suitable for the synthesis of an extracellular matrix and the formation of a construct comprising one or more layers of cells embedded in the neosynthesized endogenous extracellular matrix, and b) recovering the construct.
- This method can also comprise, before steps a) and b), the following steps a ') and b'): a ') the extraction of the cells of interest from one or more tissues, by any appropriate means, for example by enzymatic digestion, mechanical treatment, explant, etc., and b ') the amplification of said cells extracted during step a') in an appropriate medium, typically in the presence of ascorbic acid or a derivative of said acid.
- the method can also further comprise a step c) of recovering the cell construct (for example by detachment) and a step d) of artificial increase in the thickness of said construct, in particular by folding (for example by successive folding), rolling of the construct on itself or retraction of the construct.
- the cells can be extracted from the tissue chosen by any appropriate means, for example by enzymatic digestion (eg, collagenase) or by using an explant technique known to those skilled in the art. job. It can be a mechanical dissection (e.g., scalpel), an enzymatic washing, a cell concentration, a mechanical cutting (e.g., scissors), etc.
- the cells thus extracted generally consist of a population of cells of various natures, for example of mature cells and of progenitor cells. These cells are typically representative of the composition of the tissue or construct to be reconstituted.
- step b ' aims to increase the number of cells to facilitate the constitution of tissue. It can be performed for a variable period of time, for example from 1 to 10 days, or more, depending on the cell type, the quantity of cells available, etc.
- the culture medium used is typically a basic culture medium as described below (possibly supplemented with ascorbic acid or a similar molecule), which can be changed 2 or 3 times per week depending on the state of proliferation cells.
- the culture is treated to detach the adherent cells, for example by means of trypsin.
- the duration of the passage in the oven which follows and allows the detachment of the fabric will be more or less long. For example, it will be 3 minutes for endothelial cells, 5 minutes for fibroblasts, 8 minutes for keratinocytes, etc. (see examples). During this phase, the cells produce only a small amount of extracellular matrix.
- the amplified cells thus obtained are then used for the preparation of the construct. To this end, they are sown in a suitable device and cultivated under conditions suitable for the synthesis of an extracellular matrix and for the formation of a construct comprising one or more layers of cells embedded in the endogenous neosynthesized extracellular matrix.
- the cells are seeded (for example in petri dishes), at a density of between approximately 10 3 and 10 6 cells / cm 2 , preferably between 3.10 3 and 5.10 5 cells / cm 2 , typically between 3000 and 12000 cells / cm 2 . In a typical experiment, approximately 5.10 5 cells are thus used per 75 cm 2 box , for example.
- the cells are thus cultured for a sufficient time to allow
- This culture can thus be maintained for 2 to 6 weeks, optionally with gentle stirring, advantageously by renewing the medium 1 to 3 times per week.
- the cultures are advantageously carried out in a basic culture medium comprising ascorbic acid or a derivative thereof.
- Ascorbate is added to promote the hydroxylation of praline and the secretion of procollagen, the soluble precursor of collagen, but also because it constitutes an important cofactor of active enzymes at the time of the post-translational phase and upstream regulates the synthesis of type I and III collagens.
- Ascorbic acid can be replaced by one of its synthetic derivatives or by a nutrient acting on the synthesis of extracellular matrix. Therefore, the method of the invention does not require the use of exogenous matrix.
- the basic culture media used are media adapted to the cell type (s) and to the tissue or construct to be reconstituted.
- the culture medium and conditions must stimulate cell growth in constructs and the synthesis of extracellular matrix. It is preferable to choose a medium of known composition, that is to say in particular not comprising an animal organ or tissue extract, although the presence of such undefined compounds is possible if it promotes the obtaining of 'a construct according to the invention.
- Synthetic or recombinant functional equivalents known to those skilled in the art can also be added to the culture medium of known composition. Those skilled in the art can easily determine the basic compounds necessary for the culture of animal cells.
- DMEM Dulbecco's Modified Eagle's Medium
- MEM Minimal Essential Medium
- RPMI 1640 EDMEM (Iscove's Modified Dulbecco's Medium)
- Ham media in particular Ham's F-12
- NCTC 109 NCTC 109.
- a preferred base medium according to the invention is a DMEM / Ham F12 mixture (50:50 by volume).
- the medium may contain serum.
- the basic medium is typically supplemented with in particular compounds such as amino acids and in particular praline and glycine which enter into the structure of collagen, growth factors, hormones and inorganic salts.
- compounds such as amino acids and in particular praline and glycine which enter into the structure of collagen, growth factors, hormones and inorganic salts.
- Specific culture media which can be used in the context of the present invention are described in application WO96 / 21003. Other media are described in the examples.
- Cultures can be carried out in any suitable device, such as a plate, box, flask, pocket, etc. These are typically Petri dishes or the like.
- the cultures are advantageously kept in an incubator which makes it possible to control temperature, humidity and gas mixtures.
- Preferred culture conditions are, for example, a temperature between 35 and 40 ° C approximately, preferably 37 ° C approximately, an atmosphere containing from 5 to 10% CO 2 and a relative humidity comprised between approximately 75 and 95%.
- the tissue thus produced contains cells associated with a dense three-dimensional network of extracellular matrix neosynthesized by said cells.
- the cells multiply, overlap and manufacture an extracellular matrix whose composition is essentially identical to that of a natural extra-cellular matrix.
- the cell construct is prepared from cells originating in particular from the tendon or ligament, from the skin or the dermis, it thus comprises, around the third week of culture, a high proportion of collagen concentrated in particular in half of the built whose face is directly in contact with the culture support. It is at this collagen network that mineralization will be initiated.
- the cells are cultured under conditions ensuring the formation or the maintenance of the capacity of the cells to produce mineralization (or ossification).
- This capacity can be linked to the cells used, and favored by the culture in the presence of a stimulus activating or increasing the mineralization and / or the ossification of the cells, in particular of the basal progenitor cells.
- the mineralization of the tissue is surprisingly obtained by modifying the culture conditions. This mineralization concerns the neosynthesized matrix and in particular the constituent matrix of half of the construct in contact with the culture support.
- Stimulation can be obtained by bringing the construct or the cells into contact with a particular material or with particles of this material, by adding differentiation factor (s), conditioned medium, synthetic substances or even by addition of natural substances such as coral or by mechanical stimulation.
- differentiation factor s
- conditioned medium synthetic substances
- synthetic substances such as coral or by mechanical stimulation.
- mineralizing materials there may be mentioned in particular a support or particles comprising hydroxyapatite, bioactive glass (or bio-glass), a mineralized collagen substitute, a bone substitute, a ceramic, in particular based on zirconium, or coral, or any material (for example a composite material) whose surface is coated, at least in part, with one of these components.
- the mineralizing material can also be produced from an inert bio-activated material by the grafting on the surface of substances capable of inducing the mineralization of the construct.
- substances or factors which can be used there may be mentioned for example adjuvants incorporated into the culture medium and reinforcing the stimulating effect of the mineralization created by the chosen support (cytokine, dexamethasone, beta-glycerophosphate, beta-aminopropionitrile )
- the invention therefore comprises a method of preparing a mineralized or mineralizing cell construct, comprising a step of bringing the cells into contact with a stimulus such as a support or mineralizing material, particles of this material, differentiating factors, cytokines, a conditioned medium, a synthetic substance or a natural substance, stimulating the mineralization or the mineralization capacity of cells.
- a stimulus such as a support or mineralizing material, particles of this material, differentiating factors, cytokines, a conditioned medium, a synthetic substance or a natural substance, stimulating the mineralization or the mineralization capacity of cells.
- the stimulus is caused by a support or mineralizing material, advantageously comprising hydroxyapatite or bio-glass.
- the hydration of bio-glass causes its absorption, and this type of support is therefore particularly suitable and advantageous when the tissue to be reconstituted is intended to be grafted, since ultimately only the graft remains in the recipient host.
- a particular object of the invention therefore resides in a process for the preparation of a reconstructed cellular construct or tissue, comprising the in vitro culture of cells under conditions ensuring the synthesis of extracellular matrix and mineralization. It is advantageously a culture in the presence of a stimulus, such as a support, agent or mineralizing treatment, advantageously a culture on a mineralizing support or in the presence of mineralizing particles.
- a stimulus such as a support, agent or mineralizing treatment
- Obtaining a construct according to the invention having zones of mineralization does not require the addition of growth factor, such as for example TGF- ⁇ 1.
- a particular subject of the invention also relates to a cellular construct or tissue, characterized in that it is capable of being obtained by a process comprising the in vitro culture, in the absence of a synthetic matrix or framework, of cells in conditions ensuring the formation of a construct comprising one or more layers of cells embedded in an endogenous extracellular matrix, and under conditions stimulating mineralization or ossification.
- Mineralization is generally carried out or initiated at the same time as the stage of construction of the construct and synthesis of the extracellular matrix. However, mineralization generally continues after the recovery of the construct and / or its artificial thickening.
- a particular object of the invention therefore consists in placing the culture cells in the presence of mineralizing agents, for example micro or nanoparticles of bio-glass or hydroxyapatite, from the start of the culture. These agents promote the migration of progenitor cells and stimulate their capacity for mineralization and / or ossification. Such mineralization and / or ossification particularly advantageously improves the integration of the reconstituted tissue or cell construct within the tissues of the receiving host.
- mineralizing agents for example micro or nanoparticles of bio-glass or hydroxyapatite
- the mineralization can be observed by coloring using, for example, paragon or via von Kossa staining.
- periodontal cells seeded at the rate of approximately 5000 cells / cm 2 can thus be cultured for approximately three weeks, in the presence of hydroxyapatite microparticles (see FIG. 5).
- the cells in culture recognize the stimulus and produce specific enzymes of the alkaline phosphatase type.
- Phosphate substrates such as, for example, ⁇ -glycerophosphate will be hydrolyzed. They thus release phosphates capable of causing partial crystallization of the tissue by complexing with calcium ions to give calcium phosphate.
- the fabrics or constructs can be manufactured in any suitable device, such as a plate, box, flange, pocket, etc. These are typically Petri dishes or the like.
- the preparation is carried out in the absence of a synthetic three-dimensional matrix or framework.
- a particular object of the invention resides in a process for the preparation of a reconstructed construct or tissue, comprising the in vitro culture of cells derived from periodontal or cruciate ligament, under conditions ensuring the synthesis of extracellular matrix.
- the construct Once the construct has been produced, it can be recovered from the support by any known technique, typically by detachment.
- One of the characteristics of the invention resides in fact in the ease of recovery of the cell construct reconstituted by simple detachment of said construct from its culture support.
- the construct or fabric thus recovered can be treated (eg, compacted) in order to increase its thickness, typically by folding, winding, hoarding, etc.
- the thickness of the cell construct corresponds to approximately 2 or 3 layers of cells stacked on top of each other, ie approximately 30 ⁇ m.
- the cells are in fact generally maintained in culture until they have secreted a sufficient quantity of matrix to ensure minimal resistance to the cell construct. It is then possible to detach the cell construct from its culture support without it tearing, and to produce a cell construct having an increased thickness, for example from two to five times compared to a thin cultivated construct.
- a particular object of the invention also relates to cell constructs or tissues, characterized in that they are capable of being obtained by a process comprising the in vitro culture, in the absence of a synthetic matrix or framework, of cells in conditions ensuring the formation of a construct comprising one or more layers of cells embedded in an endogenous extracellular matrix, and a step of detaching the construct from its culture support, folding or rolling the construct onto itself, making it possible to produce a reconstituted tissue having increased thickness.
- Another particular object of the invention also relates to cellular constructs or tissues, characterized in that they are capable of being obtained by a process comprising the in vitro culture, in the absence of synthetic matrix or framework, of cells of periodontal or anterior ligament crossed under conditions ensuring the formation of a construct comprising one or more layers of cells embedded in an endogenous extracellular matrix, and, preferably, a step of detaching the construct from its culture support, folding or rolling of the built on itself, making it possible to produce a reconstituted tissue having an increased thickness.
- constructs according to the invention can be maintained in culture for a variable period, typically in the presence of medium, to promote cell reorganization, the continuation of mineralization, etc. Constructed or tissues can then be used for clinical (graft, implant) or pharmaceutical applications.
- constructs or tissues according to the invention can be stored in any suitable device, in the presence of culture medium, nutritive medium or isotonic saline solutions.
- the tissues are preserved or maintained in boxes, tubes, flasks, ampoules, bags, etc., preferably in the presence of a large amount of medium.
- the fabrics can be used extemporaneously or stored, preferably in the cold.
- constructs or tissues described above can be used in the field of transplants or implantology as well as in the pharmaceutical industry, for the study of tissues and the analysis of the toxic or beneficial profile of molecules, in particular of drugs. candidates.
- a tissue or construct according to the invention can thus be used in the field of transplants or implantology.
- the fabric or construct is preferably in this case of substantial thickness, typically of approximately 100 ⁇ m. It can thus advantageously be a compacted construct, eg folded or rolled on itself so as to increase its thickness by fusion and reshaping of the different cellular layers as described above, or simply detached from the support to form a cell cluster.
- the constructs of the invention can be used as such, in the form of dressings or cellular "patches", or to coat or cover all or part of an implant intended to be introduced into a subject.
- the tissue or cell construct according to the invention can be directly used in the context of a transplant.
- the invention indeed proposes the production of a cell dressing, essentially comprising a cell mass as defined above.
- An object of the invention therefore resides in particular in a pharmaceutical composition comprising a construct or tissue as described above. It is advantageously a thick or compacted fabric as described above.
- the dressing can be applied directly to a cavity or to injured tissue during simple surgical operations.
- the dressing of the invention can be used in the context of the treatment of periodontal pockets.
- ligament cells it is possible to reconstitute or repair a ligament such as the anterior cruciate ligament for example.
- a graft can also be directly envisaged at the level of the site reached by the receiving host.
- the invention therefore also provides a method of tissue treatment or repair, comprising the preparation of a tissue reconstituted by in vitro culture as described above, and the injection of this tissue, optionally after packaging in any acceptable solution or vehicle on the pharmaceutical plan.
- the tissue can possibly be associated with an exogenous matrix, such as collagen.
- the fabric or construct of the invention is used for the preparation of an implant, in particular for covering or coating all or part of an implant.
- an implant can be a dental implant (cf.: example 4 relating to the "ligaplant"), ligament, a bone or cartilaginous prosthesis, etc.
- the construct produced is typically arranged or wrapped around the structure of the implant.
- a dental implant can for example comprise a coronary part on which the crown of the tooth to be replaced will be fixed and a radicular part corresponding to the root of said tooth and around which it is possible to roll a cell construct according to the invention.
- the present invention therefore relates to a method of preparing an implant using a construct as described above, comprising winding said construct on the surface of the implant and culturing said implant associated with said constructed under conditions making it possible to maintain or stimulate the proliferation and / or differentiation of cells while promoting the fusion and remodeling of the different cellular layers of said construct on the surface of the implant.
- This construct can in particular be reconstructed from periodontal cells cultivated for approximately three weeks under the conditions indicated above (see also Figure 4).
- the mineralized face of the cell construct which corresponds to that exposed to the culture support is then exposed directly to the implant, in an amplification medium and in the presence of ascorbic acid.
- This face of the cell construct then allows the entire construct to adhere to the implant in a stable, solid and particularly advantageous manner, in particular thanks to the progenitor cells which will increase in number around said implant and will facilitate the mineralization initiated by the matrix and the collagen network.
- the structure thus reconstituted is then very close to the natural cement of the tooth.
- the amplification medium facilitates the fusion and the reshaping of the different cellular layers of the construct, insofar as no nutritional limit is imposed.
- the mineralized tissue according to the invention thus generally improves the integration of the implant in the recipient alveolar site.
- a construct according to the invention can therefore be used to prepare a dental or ligament implant for example.
- tissue or cell construct for the study of tissues and the analysis of the toxic or beneficial profile of molecules.
- the reconstituted tissues of the invention (or a part thereof) are brought into contact with one or more test compounds, and the effect of said test compound is determined, for example so to characterize the cellular reactions with regard to this or these test compounds.
- the test compound can be very varied in nature. Thus, it can be an isolated compound or a mixture of substances.
- the compound can be chemical or biological in nature. It may especially be a peptide, polypeptide, nucleic acid, lipid, carbohydrate, a chemical molecule, plant extracts, combinatorial banks, etc.
- the test compound can also be a treatment applied to tissues (radiation, UV, etc.).
- test compound can be applied at different concentrations, chosen by the user.
- the present invention therefore relates to the use of a reconstituted tissue as defined above, for the evaluation (in vitro or ex vivo) of the biological and / or toxic properties of a test compound, in particular of molecules intended for therapeutic use.
- kits for the implementation of the preparation and study processes and also for the use of the reconstituted tissues as described above advantageously include a container and / or culture reagents, and / or a tissue construct as defined above.
- Figure 1 Cells extracted from a periodontal ligament seeded at 5000 cells / cm 2 on D2 (A) after three weeks of culture (B). The cells multiply, overlap and synthesize the extra-cellular matrix.
- Figure 2 Macroscopic appearance of a construct after three weeks of static culture in a 100 mm diameter petri dish.
- Figure 3 Mineralized tissue. The Paragon coloration makes it possible to visualize the mineralization deposits.
- Figure 4 Dental implant and association of a tissue according to the invention with the dental implant.
- FIG. 5 Tissue mineralized by the addition of hydroxyapatite for the treatment of periodontal pockets. Periodontal cells are cultured in the presence of micro-particles of hydroxyapatite for three weeks. The neosynthesized collagen matrix contains deposits of mineralization (von Kossa coloration).
- FIG. 6 Histological section (magnification X100) of a construct constructed from cells of the periodontal ligament (cells of the cemento-amelar junction) cultivated on the surface of a support for hydroxyapatite, according to the method of the invention, and implanted under the skin of an athymic mouse (Swiss nu nu) for 12 weeks. The inclusion is carried out in paraffin after demineralization of the sample and the coloring is carried out with Masson trichrome.
- the tissue structure obtained is comparable to that of a fibrillar cell cement like that which exists on a normal tooth.
- Figure 7 This figure represents a tissue of a simple sheet, marked by immunohistochemistry to detect type V collagen.
- the light gray color represents the counterstaining and the dark gray color the marking of type V collagen.
- Figure 8 This figure represents a fabric identical to that of Figure 7 after being folded or rolled.
- the profile of the marking thus shows the remodeling (without preserving the polarity of each folding of the fabric).
- the light gray color represents the counter coloration and the dark gray color the marking of type V collagen.
- the media and / or products used e.g., vitamin C, ascorbic acid 2-phosphate, collagenase, dexamethasone, etc.
- vitamins C e.g., vitamin C, ascorbic acid 2-phosphate, collagenase, dexamethasone, etc.
- These substances are generally sterilized before use.
- the collagenase A (clostridiopeptidase A) used is a bacterial protease produced by clostridium histolyticum. This protease has specificity for the X-Gly links of the Pro-X-Gly-Pro sequences (X representing a neutral amino acid) found in the collagen triple helices.
- Collagenase is not inhibited by serum but by EDTA and is activated by calcium. Its optimal pH is between 6 and 8. In lyophilized form, it is stable between +2 and + 8 ° C and in solution between -15 ° and -25 ° C. Collagenase can be reconstituted in buffered solutions, such as PBS, HBSS or DMEM / F12, which contain calcium.
- Dexamethasone is a glucocorticoid with a PM of 392.5, which increases the level of alkaline phosphatase. It is prepared from a commercial source (Sigma D-2915). The ⁇ -glycerophosphate, whose MW is 216, is hydrolyzed by alkaline phosphatase into phosphate ions, necessary for good mineralization. It is prepared from commercial sources (Sigma G-9891).
- Antibiotic-free media are prepared 1 or 2 days before use, so that sterility can be checked. They are homogenized and controlled. Antibiotics are added extemporaneously at the time of use of the medium. Bacteriological control is carried out according to conventional methods. Storage is typically between + 2 ° C and + 8 ° C.
- the dental tissues obtained are kept in a transport medium until they are processed, if possible within 24 hours of receipt.
- the tissues are then washed 3 times in PBS, in the presence of antibiotics, so as to remove the excess blood.
- the roots of the teeth are then placed in 60 mm diameter petri dishes, for example with approximately 5 ml of collagenase A (see the paragraph relating to the media).
- the teeth are scraped with a scalpel from half the root to its lower end, until small fragments of cement and dentin are obtained.
- the fragments are incubated overnight at 37 ° C (approximately between 16 and 20 hours) in a CO 2 incubator.
- the cells and the tissue fragments are put in a tube, centrifuged and resuspended in culture medium.
- the suspension of cells and debris is then reseeded into the extraction petri dish with 4 ml of medium. of culture.
- the culture medium is changed 2 or 3 times a week depending on the state of proliferation of the cells.
- the culture is maintained between 10 days and 3 weeks approximately before being ready to be trypsinized.
- the petri dish should preferably have approximately 50% confluence.
- the cultured cells are pre-confluent or confluent, they are treated according to the following steps:
- the culture dish is rinsed with PBS culture, then trypsin-EDTA is added so as to cover the entire culture (approximately 5 ml per 75 cm 2 ).
- the flanges are placed in the oven at 37 ° C.
- the time will be more or less long, preferably less than approximately 5 minutes for endothelial cells or fibroblasts, and less than approximately
- the supernatant is removed and an amount of culture medium is added so as to have a suspension containing 100,000, 1 million or 10 million cells per ml as required.
- the final suspension can be made at different concentrations as required.
- the fabric produced contains cells associated with a dense three-dimensional network of extracellular matrix neosynthesized by these same cells.
- This extracellular matrix is produced following stimulation of cells by ascorbic acid, a synthetic derivative of this product or a nutrient acting on the synthesis of extracellular matrix, without resorting to the addition of exogenous matrix.
- This fabric is produced in culture devices, porous or not, of various sizes according to the desired dimensions.
- the fibroblasts are seeded at a density between 3000 and 12000 cells / cm2.
- the culture medium is changed regularly, for example 3 times a week for 2 to 6 weeks, with or without agitation of the cultures, so as to maintain environmental (physico-chemical) and nutritional conditions favorable to the development of the culture.
- the cells involved in tissue reconstruction can come from the same cell population or from different cell populations, thus forming a heterogeneous population. They can be periodontal ligament fibroblasts, cementoblasts, odontoblasts, ameloblasts, pulp cells, ligament and tendon fibroblasts, chondrocytes, osteoblasts, mesenchymal stem cells, marrow extracts bone, of any other cell type having the capacity to mineralize in particular under the influence of external factors or a mixture of said cells.
- the tissue can be composed of several cell types which do not have the capacity to mineralize, but which can be stimulated so as to cause this mineralization. They may for example be skin fibroblasts and / or muscle cells.
- the tissue can be composed of several cell types at the same time, distributed evenly or not.
- the mineralization of the tissues can be obtained by modifying the culture conditions so as to cause the mineralization of the neosynthesized matrix.
- This stimulation can be obtained by contact with a material or particles of this same material and / or by the addition of differentiation factors, cytokines, conditioned medium, dexamethasone, beta-glycerophosphate, beta-aminopropionitrile, by l 'addition of synthetic substances such as calcium phosphate, calcium carbonate, hydroxyapatite, bioactive glass (bioactive glass), ceramics, natural substances of the coral type but also by mechanical stimulation.
- Obtaining a construct according to the invention having zones of mineralization does not require the addition of growth factor, such as for example TGF- ⁇ 1.
- EXAMPLE 3 Implantation of a construct in vivo
- This example describes the in vivo introduction of an implant of the invention comprising a tissue construct.
- the construct was prepared as described in Examples 1 and 2 from human periodontal ligament (PDL) cells, then wound around a bio-glass implant (45 S 5).
- the construct was stored in DMEM medium supplemented with antibiotic (gentamycin).
- antibiotic gentamycin
- Male athymic mice (Swiss NU / NU 4 weeks) were anesthetized.
- a subcutaneous implantation, at the dorsal level, was performed. For this, 4 bags are prepared on each mouse, under sterile conditions. The implants are placed in these pockets, which are then sutured. A bandage was placed over the sutured area.
- mice were sacrificed, and the constructs were recovered with the adjacent tissue of murine origin. The whole was included in resin after fixing. Cups were produced and colored in Paragon. The sections are analyzed, and the constructs obtained are compared with those produced from skin fibroblasts, treated in a similar manner, and with constructs which have not undergone implantation. Histological sections show that the constructs derived from PDL according to the invention and implanted in mice have dense fibrillar structures, similar to those found in a native periodontal ligament. The results obtained also show that the set of fibers is anchored to the surface of the implant by a thick layer of mineralization, of cellular origin. These tissue structures are absent from other preparations.
- the "Ligaplant” is a product intended to replace a lost tooth in a patient, it associates a ligament reconstituted from the cells of this patient, with an implant produced from a biomaterial.
- the periodontal ligament is a ligament, which is anchored on the root, mainly by cellular and acellular fibrillar cements. This ligament is also attached to the bone of the alveoli by a fibrillar structure embedded in the bone (Sharpey fibers).
- the ligament is reconstructed on the surface of an implant, meeting the conditions so that an anchor close to the cementum is synthesized in vitro, before the reimplantation of the product. Restoration of the anchor on the side of the cell will be done once the product is reimplanted. The presence of this newly formed tissue structure guides the healing process, avoiding osseointegration of the implant.
- Use of the patient's cells to reconstruct the ligament part of the Ligaplant makes it an autologous product.
- a heterogeneous population is extracted from the surface of the lost tooth by scraping the middle part of the root.
- This population includes the main cell types of PDL: fibroblasts, cementoblasts, endothelial cells, and progenitors of these different cell types. The presence of these cells is confirmed both by observation under light microscopy, but also by the results of molecular biology analyzes performed on this population directly obtained from the biopsy extracted from the root surface.
- RT-PCR detection of messenger RNAs coding for alkaline phosphatase, osteocalcin (OCN), osteopontin (OPN), bone sialoprotein (BSP) and type I collagen confirms both this heterogeneity of the population by the diversity of the cellular markers expressed, but also the possibilities, which exist, of reconstruction of the PDL from these cells.
- OCN osteocalcin
- OPN osteopontin
- BSP bone sialoprotein
- the biopsy collected on the surface of the root of the lost tooth is treated with collagenase, so as to accelerate the extraction of the cells.
- collagenase neither diminishes the proliferative capacities of the cells nor their capacities to express specific functions (mineralization and production of extra cellular matrix).
- the cell population is first amplified so as to increase the number of cells harvested. Cell proliferation is maintained at a high level in the exponential phase of the growth curve by repeated passages, performed before the culture reaches confluence.
- the culture conditions cause a selection of cells: the endothelial cells disappear, in fact they can neither adhere to the support, nor proliferate, while the fibroblasts actively multiply .
- the presence of cementoblasts is detectable by the level of expression of the mineralization markers which are specific to them.
- the difference in morphology of the cementoblasts, which made it possible to identify them under the microscope, has disappeared, tending to prove that their shape has evolved into a spindle shape similar to that of fibroblasts.
- This is a common phenomenon, observed during the culture of cells present in mineralized tissue structures, of the chondrocyte, osteocyte type.
- this dedifferentiation of cementoblasts seems limited to their morphology. Indeed, the production of mineralization zones, induced in vitro by the addition of ⁇ -glycerophosphate to the culture medium, proves the functionality of these cells.
- the cells are not peeled but left in the petri dish in the presence of a proliferation medium supplemented with vitamin C to stimulate cellular matrix synthesis extra.
- a continuous carpet is formed, after 3 weeks of culture, consisting of several layers of cells enclosed in a dense extracellular matrix.
- the culture is prolonged beyond the confluence so as to induce a significant production of extra cellular matrix.
- the culture is structured and takes the form of a thick sheet made up of cells inside a dense extracellular matrix.
- This sheet is detached from the bottom of the box by mechanical means (rolling). It can then be handled, given its good properties mechanical. A 15 cm 2 piece of this sheet is cut using a scalpel. It is wrapped in several layers around the implant (cylinder 5 mm in diameter and 11 mm long) and constitutes the cellular part of the "Ligaplant".
- the future “Ligaplant” is ready for an ultimate phase of differentiation which should allow the cells to produce a mineral anchor.
- This phase is obtained by cultivating this construct in an environment favorable to mineralization for 2 weeks.
- the anchoring of the sheet on the implant is obtained by synthesis of a mineralization of the ECM by the cells, in the presence of a culture medium containing 10 mM of ⁇ -glycerophosphate.
- the nature of the cell-implant interface guides this mineralization.
- Calcium phosphate ceramics can thus be used to obtain a direct link with a mineralizing tissue.
- the cells react on contact with this biomaterial, producing a mineral bonding layer from which a cementum is reconstructed when the product is placed in vivo.
- the inventors proceeded to the subcutaneous implantation in the skull of nude mice (Swiss nu nu) of sheet constructions -implant.
- the evolution of these constructions was evaluated in kinetic form, with points taken at 4, 8 and 12 weeks after implantation, by varying different parameters such as the origin of the biopsy (apex, central area of the root, collar), the nature of the material constituting the implant (dentin, hydroxyapatite, titanium coated with calcium phosphate).
- the intensity of the mineralization of the MEC was measured by appropriate treatments of the histological sections.
- the results obtained show a gradual evolution over time of the thickness of the mineralized layers present at the interface of hydroxyapatite. As this process develops, collagen fibers embedded in this mineral substrate appear markedly. It is possible to observe in places the presence of cells included in the mineral part. These structural elements are present on the entire cell-biomaterial interface.
- the conclusions of this histological analysis show that a characteristic tissue of the fibrillar cell cement, with a significant amount of Sharpey fibers, is reconstructed by the PDL cells and constitutes an anchoring of the sheet on the implant.
- the constituent material As the implant is subjected to heavy loads, the constituent material has been selected to obtain optimal bio-compatibility while retaining a mechanical resistance comparable to that of implants of the “osteo-integrated” type.
- the material which was chosen to constitute the implant is produced by bio activation of titanium.
- the naturally produced anchor apatite layer is very thin ( ⁇ 1 ⁇ m), which eliminates the risk of fragile rupture in the layer (71) and preserves the micro-roughness of the implant surface (and therefore the bond mechanical between the metallic and mineral phases).
- the titanium-apatite bond is a bond of resistant covalent type which constitutes a continuous transition between the 2 phases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Rehabilitation Therapy (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0116265A FR2833610B1 (fr) | 2001-12-14 | 2001-12-14 | Construits cellulaires cultives in vitro, preparation et utilisations |
| FR0116265 | 2001-12-14 | ||
| PCT/FR2002/004360 WO2003052084A2 (fr) | 2001-12-14 | 2002-12-13 | Construits cellulaires cultives in vitro, preparation et utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1453955A2 true EP1453955A2 (fr) | 2004-09-08 |
Family
ID=8870550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02804924A Withdrawn EP1453955A2 (fr) | 2001-12-14 | 2002-12-13 | Construits cellulaires cultives in vitro, preparation et utilisations |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050053585A1 (fr) |
| EP (1) | EP1453955A2 (fr) |
| CN (1) | CN1604962A (fr) |
| AU (1) | AU2002364653B2 (fr) |
| BR (1) | BR0214860A (fr) |
| CA (1) | CA2469611A1 (fr) |
| FR (1) | FR2833610B1 (fr) |
| IL (1) | IL162343A0 (fr) |
| PL (1) | PL370703A1 (fr) |
| WO (1) | WO2003052084A2 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416801C (fr) * | 2000-07-21 | 2012-01-03 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cellules souches humaines, adultes, de la pulpe dentaire in vitro et in vivo |
| EP2266500B1 (fr) * | 2003-08-01 | 2015-04-01 | CellSeed Inc. | Structure tridimensionnelle de tissus |
| EP1748064B1 (fr) * | 2004-04-25 | 2019-04-17 | CellSeed Inc. | Feuille de cellules de ligament parodontal en culture, procédé de production et utilisation de celle-ci |
| EP1934332B1 (fr) * | 2005-09-30 | 2011-02-23 | Global Dental ApS | Procede de differentiation des cellules souches et son utilisation pour le traitement d'etats dentaires |
| EP1998787A4 (fr) | 2006-03-03 | 2010-04-21 | Organogenesis Inc | Régénération et réparation de tissu oral |
| WO2008097906A2 (fr) | 2007-02-02 | 2008-08-14 | The Regents Of The University Of Michigan | Système et procédé pour former des constructions d'os, de ligament et de ligament osseux |
| CN101134946B (zh) * | 2007-08-03 | 2011-12-21 | 陆洪光 | 一种黑色素瘤体外模型的制作方法 |
| CA2695863A1 (fr) * | 2007-08-08 | 2009-02-12 | Pervasis Therapeutics, Inc. | Materiaux et procedes pour traiter un dommage cause au systeme squelettique et favoriser une reparation et une regeneration du systeme squelettique |
| ES2536633T3 (es) * | 2007-11-19 | 2015-05-27 | Ben Gurion University Of The Negev Research And Development Authority | Efectos mediados por calcio de corales y métodos de uso de los mismos |
| WO2009151678A1 (fr) * | 2008-03-11 | 2009-12-17 | Massachusetts Institute Of Technology | Surfaces sensibles aux stimuli |
| DE102008049014A1 (de) * | 2008-09-25 | 2010-04-22 | Bagambisa, Frank, Dr. | Dentalimplantat zur Implantation in einen menschlichen oder tierischen Kieferknochen und Verfahren zu seiner Herstellung |
| CN102068318B (zh) * | 2010-12-21 | 2012-11-21 | 四川大学 | 生物牙根支架材料的构建方法 |
| CN103611193B (zh) * | 2013-11-26 | 2015-05-27 | 中山大学 | 一种碳酸钙微球-细胞外基质复合材料及其制备方法和应用 |
| US20180303974A1 (en) | 2015-11-03 | 2018-10-25 | Ariel-University Research And Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
| NL2025818B1 (en) * | 2020-06-11 | 2022-02-16 | Umc Utrecht Holding Bv | Improved adhesive drug carrier |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891558A (en) * | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
| CA2198978A1 (fr) * | 1996-03-01 | 1997-09-01 | Clemens Antoni Van Blitterswijk | Methode pour la production d'os in vitro |
| EP2295540A1 (fr) * | 1998-11-19 | 2011-03-16 | Organogenesis, Inc. | Constructions de tissu issues de la bioingénierie et leurs procédés de fabrication et d'utilisation |
| US6287340B1 (en) * | 1999-05-14 | 2001-09-11 | Trustees Of Tufts College | Bioengineered anterior cruciate ligament |
| US6233476B1 (en) * | 1999-05-18 | 2001-05-15 | Mediguide Ltd. | Medical positioning system |
| US6479064B1 (en) * | 1999-12-29 | 2002-11-12 | Children's Medical Center Corporation | Culturing different cell populations on a decellularized natural biostructure for organ reconstruction |
-
2001
- 2001-12-14 FR FR0116265A patent/FR2833610B1/fr not_active Expired - Fee Related
-
2002
- 2002-12-13 CN CNA028250338A patent/CN1604962A/zh active Pending
- 2002-12-13 EP EP02804924A patent/EP1453955A2/fr not_active Withdrawn
- 2002-12-13 PL PL02370703A patent/PL370703A1/xx not_active Application Discontinuation
- 2002-12-13 CA CA002469611A patent/CA2469611A1/fr not_active Abandoned
- 2002-12-13 IL IL16234302A patent/IL162343A0/xx unknown
- 2002-12-13 US US10/498,264 patent/US20050053585A1/en not_active Abandoned
- 2002-12-13 WO PCT/FR2002/004360 patent/WO2003052084A2/fr not_active Ceased
- 2002-12-13 AU AU2002364653A patent/AU2002364653B2/en not_active Ceased
- 2002-12-13 BR BR0214860-9A patent/BR0214860A/pt not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO03052084A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003052084A3 (fr) | 2003-12-11 |
| PL370703A1 (en) | 2005-05-30 |
| CN1604962A (zh) | 2005-04-06 |
| AU2002364653A1 (en) | 2003-06-30 |
| IL162343A0 (en) | 2005-11-20 |
| FR2833610B1 (fr) | 2007-01-26 |
| FR2833610A1 (fr) | 2003-06-20 |
| AU2002364653B2 (en) | 2007-10-18 |
| CA2469611A1 (fr) | 2003-06-26 |
| WO2003052084A2 (fr) | 2003-06-26 |
| BR0214860A (pt) | 2004-12-14 |
| US20050053585A1 (en) | 2005-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2139864C (fr) | Utilisation d'un materiau poreux a base de carbonate de calcium comme support pour un facteur de croissance dans la preparation d'un implant bioresorbable | |
| Rosa et al. | Tissue engineering: from research to dental clinics | |
| EP1453955A2 (fr) | Construits cellulaires cultives in vitro, preparation et utilisations | |
| CN101970022A (zh) | 根管填充材料以及牙组织再生方法 | |
| Kiarashi et al. | Mesenchymal stem cell-based scaffolds in regenerative medicine of dental diseases | |
| Furukawa et al. | Scaffold-free cartilage by rotational culture for tissue engineering | |
| US20040030404A1 (en) | Method for cultivating a cartilage replacement and a biomatrix produced according to this method | |
| Zhou et al. | Periodontal healing by periodontal ligament cell sheets in a teeth replantation model | |
| JPWO2015199245A1 (ja) | インプラント培養歯根膜細胞シート複合体、その製造方法及びその利用方法 | |
| CN118846238A (zh) | 用于骨组织工程的生物材料 | |
| Zhu et al. | Three-dimensionally printed porous biomimetic composite for sustained release of recombinant human bone morphogenetic protein 9 to promote osteointegration | |
| EP1934332B1 (fr) | Procede de differentiation des cellules souches et son utilisation pour le traitement d'etats dentaires | |
| JP3897717B2 (ja) | 細胞移植治療材料およびその製造方法 | |
| Li et al. | Tooth and dental pulp regeneration | |
| Guo et al. | Human periodontal ligament cells reaction on a novel hydroxyapatite–collagen scaffold | |
| Han et al. | Upregulation of bone-like extracellular matrix expression in human dental pulp stem cells by mechanical strain | |
| EP1960011B1 (fr) | Utilisation d' un polysaccharide excrete par l'espece vibrio diabolicus a des fins d'ingenierie des tissus conjonctifs non mineralises | |
| Sureshchandra et al. | Regeneration of dental pulp: A myth or hype | |
| Hancox et al. | Scaffolds for dental cementum | |
| Li et al. | Periodontal tissue engineering: current approaches and future therapies | |
| Bates et al. | Cell-based regenerative approaches to the treatment of oral soft tissue defects. | |
| JP2005512541A (ja) | インビトロ培養した細胞構築物、その調製および使用 | |
| Hammad | Reconstruction of auricular cartilage using natural-derived scaffolds with an in vivo application in rabbit model | |
| Wang et al. | Three-dimensional culture of human periodontal ligament cells on highly porous polyglycolic acid scaffolds in vitro | |
| KR20070035592A (ko) | 지방형성 중간엽 줄기 세포를 포함하는 폴리(에틸렌글리콜)-디아크릴레이트-(pegda)-가교된 하이드로겔 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20040522 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
| 17Q | First examination report despatched |
Effective date: 20050527 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HENKEL KGAA |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HENKEL AG & CO. KGAA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20110701 |